Trial Title:
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT ID:
NCT06305767
Condition:
Bladder Cancer
Conditions: Official terms:
Urinary Bladder Neoplasms
Pembrolizumab
Conditions: Keywords:
Programmed Cell Death-1 (PD1, PD-1)
Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
The Phase 2 Adjuvant Cohort is a placebo- and active-controlled, parallel-group,
multicenter, double-blind safety and efficacy study of adjuvant V940 plus pembrolizumab
versus adjuvant placebo plus pembrolizumab in participants with pathologic high-risk MIUC
after radical resection. Eligible participants will be randomly assigned in a 1:1 ratio
to receive treatment with either V940 plus pembrolizumab or placebo plus pembrolizumab.
The Phase 1 Perioperative Cohort of this study has a single arm into which eligible
participants are allocated. It will evaluate safety and preliminary efficacy of
perioperative (neoadjuvant and adjuvant) V940 in combination with pembrolizumab plus EV
for participants with muscle-invasive bladder cancer (MIBC).
Primary purpose:
Treatment
Masking:
Double (Participant, Investigator)
Masking description:
The Phase 2 Adjuvant Cohort of study will be conducted as a double-blind study under
in-house blinding procedures. V940 and placebo will be prepared and dispensed by
unblinded pharmacists and administered in a blinded fashion by blinded personnel. The
participants and the investigators who are involved in the study intervention
administration will be unaware of the intervention assignments.
The Phase 1 Perioperative Cohort will be conducted as an open-label study. Participants
and investigators will be aware of the intervention assignments.
Intervention:
Intervention type:
Biological
Intervention name:
Pembrolizumab
Description:
Administered via IV infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to
9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of
every 3-week cycle for up to 4 neoadjuvant cycles, and up to 13 adjuvant cycles for
Perioperative Cohort participants.
Arm group label:
Adjuvant Cohort: Pembrolizumab + Placebo
Arm group label:
Adjuvant Cohort: Pembrolizumab + V940
Arm group label:
Perioperative Cohort: Pembrolizumab + V940 + Enfortumab Vedotin (EV) and Surgery
Other name:
MK-3475
Other name:
Keytruda®
Intervention type:
Biological
Intervention name:
V940
Description:
Administered via IM injection at a dose of 1 mg every 3 weeks for a total of up to 9
adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a
total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort
participants.
Arm group label:
Adjuvant Cohort: Pembrolizumab + V940
Arm group label:
Perioperative Cohort: Pembrolizumab + V940 + Enfortumab Vedotin (EV) and Surgery
Intervention type:
Other
Intervention name:
Placebo
Description:
V940 diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9
doses.
Arm group label:
Adjuvant Cohort: Pembrolizumab + Placebo
Intervention type:
Biological
Intervention name:
Enfortumab Vedotin
Description:
Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every 3-week
cycle for up to 4 neoadjuvant cycles, and up to 5 adjuvant cycles for Perioperative
Cohort participants.
Arm group label:
Perioperative Cohort: Pembrolizumab + V940 + Enfortumab Vedotin (EV) and Surgery
Other name:
PADCEV®
Intervention type:
Procedure
Intervention name:
Surgery (RC plus PLND)
Description:
Curative intent surgery (RC plus PLND) will be administered to all participants in the
Perioperative Cohort and will be done in accordance with the American Urological
Association/American Society for Radiation Oncology/American Society of Clinical
Oncology/Society of Urologic Oncology guidelines.
Arm group label:
Perioperative Cohort: Pembrolizumab + V940 + Enfortumab Vedotin (EV) and Surgery
Summary:
Researchers are looking for new ways to treat people with high-risk muscle-invasive
urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins
in cells that line the inside of the bladder and other parts of the urinary tract, such
as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy
before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to
destroy cancer cells or stop them from growing. After surgery, some people receive more
treatment to prevent cancer from returning. Pembrolizumab is an immunotherapy, which is a
treatment that helps the immune system fight cancer. Enfortumab vedotin (EV) is an
antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers
treatment to destroy those cells. Researchers want to learn if giving V940 (the study
treatment) with pembrolizumab can prevent MIUC from returning after surgery. V940 (also
called mRNA-4157) is designed to treat each person's cancer by helping the person's
immune system identify and kill cancer cells based on certain proteins found on those
cancer cells.
The goals of this study are to learn if people who receive V940 and pembrolizumab are
alive and cancer free longer than those who receive placebo and pembrolizumab, and to
learn about the safety of V940, pembrolizumab, and EV, and if people tolerate them.
Detailed description:
Enrollment of participants into the Phase 1 Perioperative Cohort of this study is planned
to start in approximately February of 2025.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Must provide blood samples per protocol, to enable V940 production, and circulating
tumor deoxyribonucleic acid testing
- Has an Eastern Cooperative Oncology Group performance status of 0 to 2 assessed
within 7 days before randomization
- Must provide a formalin-fixed paraffin-embedded tumor tissue sample for next
generation sequencing
Adjuvant Cohort:
- Has MIUC
- Has dominant histology of urothelial carcinoma (UC)
- Has high-risk pathologic disease after radical resection
- For participants who have not received cisplatin-based neoadjuvant chemotherapy, are
ineligible to receive cisplatin according to protocol pre-defined criteria
Perioperative Cohort:
- Has MIBC
- Has a histological diagnosis of UC
- Is deemed eligible for RC and PLND and agrees to undergo curative intent standard RC
and PLND and neoadjuvant and adjuvant treatment per protocol
- Is ineligible to receive cisplatin according to protocol pre-defined criteria
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has received a live or live-attenuated vaccine within 30 days before the first dose
of study intervention
- Has known additional malignancy that is progressing or has required active treatment
≤3 years prior to study randomization
- Has current pneumonitis/interstitial lung disease
- Has active infection requiring systemic therapy
- Has active hepatitis B and hepatitis C virus infection
Adjuvant Cohort:
- Has received prior systemic anticancer therapy
- Has received prior neoadjuvant therapy, with the exception of neoadjuvant
cisplatin-based chemotherapy for MIUC
- Has severe hypersensitivity to either V940 or pembrolizumab (MK-3475) and/or any of
their excipients
Perioperative Cohort:
- Has received any prior systemic treatment, cancer vaccine treatment, chemoradiation,
and/or radiation therapy treatment for MIBC
- Has severe hypersensitivity to either V940, pembrolizumab, or EV and/or any of their
excipients
- Has ongoing sensory or motor neuropathy
- Has active keratitis or corneal ulcerations
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102)
Address:
City:
Orlando
Zip:
32804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
205-520-6512
Facility:
Name:
University of Chicago Medical Center ( Site 0109)
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
773-702-4400
Facility:
Name:
University of Iowa ( Site 0110)
Address:
City:
Iowa City
Zip:
52242
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
319-230-8823
Facility:
Name:
Icahn School of Medicine at Mount Sinai ( Site 0101)
Address:
City:
New York
Zip:
10029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
212-824-8583
Facility:
Name:
Duke Cancer Institute ( Site 0107)
Address:
City:
Durham
Zip:
27710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
919-681-8602
Facility:
Name:
Cleveland Clinic Main ( Site 0100)
Address:
City:
Cleveland
Zip:
44195
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
216-296-5457
Facility:
Name:
Fox Chase Cancer Center ( Site 0106)
Address:
City:
Philadelphia
Zip:
19111
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
215-728-3889
Facility:
Name:
Houston Methodist Hospital-Department of Urology ( Site 0111)
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
346-266-6777
Facility:
Name:
Macquarie University-MQ Health Clinical Trials Unit ( Site 1803)
Address:
City:
Macquarie University
Zip:
2109
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+61 2 9812 2956
Facility:
Name:
Westmead Hospital-Department of Medical Oncology ( Site 1802)
Address:
City:
Westmead
Zip:
2145
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+61 2 8890 8383
Facility:
Name:
One Clinical Research ( Site 1807)
Address:
City:
Nedlands
Zip:
6009
Country:
Australia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+61862799466
Facility:
Name:
BC Cancer Vancouver ( Site 0004)
Address:
City:
Vancouver
Zip:
V5Z 4E6
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
6048776000
Facility:
Name:
Centre Hospitalier de l'Université de Montréal ( Site 0005)
Address:
City:
Montréal
Zip:
H2X 3E4
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
5148908000
Facility:
Name:
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Address:
City:
Quebec City
Zip:
G1J 1Z4
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
4185254444
Facility:
Name:
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer
Address:
City:
Sherbrooke
Zip:
J1H 5H4
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
819-346-1110 ext. 13446
Facility:
Name:
FALP ( Site 1500)
Address:
City:
Santiago
Zip:
7500921
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56956075934
Facility:
Name:
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 1503)
Address:
City:
Santiago
Zip:
8330032
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56942477513
Facility:
Name:
Bradfordhill-Clinical Area ( Site 1501)
Address:
City:
Santiago
Zip:
8420383
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
56998744662
Facility:
Name:
ONCOCENTRO APYS-ACEREY ( Site 1506)
Address:
City:
Viña del Mar
Zip:
2520598
Country:
Chile
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+56992369820
Facility:
Name:
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1605)
Address:
City:
Valledupar
Zip:
200001
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+57 312 8385292
Facility:
Name:
Clínica Universitaria Colombia ( Site 1600)
Address:
City:
Bogotá
Zip:
111321
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
573103469453
Facility:
Name:
Fundacion Valle del Lili- CIC-Oncology CIC ( Site 1608)
Address:
City:
Cali
Zip:
760032
Country:
Colombia
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
57 3162801914
Facility:
Name:
Oncopole Claudius Regaud ( Site 0302)
Address:
City:
Toulouse
Zip:
31059
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33531155151
Facility:
Name:
Gustave Roussy ( Site 0303)
Address:
City:
Villejuif
Zip:
94800
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33142115348
Facility:
Name:
Institut de Cancérologie de l'Ouest ( Site 0300)
Address:
City:
ANGERS cedex 02
Zip:
49055
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
33241352734
Facility:
Name:
Hopital Claude Huriez - CHU de Lille ( Site 0301)
Address:
City:
Lille
Zip:
59037
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0320444398
Facility:
Name:
Hôpital Saint-Louis ( Site 0304)
Address:
City:
Paris
Zip:
75475
Country:
France
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+33633211534
Facility:
Name:
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Sit
Address:
City:
Munich
Zip:
81675
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
498941402522
Facility:
Name:
Caritas-Krankenhaus St. Josef-Klinik fuer Urologie ( Site 0404)
Address:
City:
Regensburg
Zip:
93053
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
09417823505
Facility:
Name:
Universitätsklinikum Halle-Universitätsklinik und Poliklinik für Urologie ( Site 0402)
Address:
City:
Halle
Zip:
06120
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+493455575810
Facility:
Name:
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405)
Address:
City:
Dresden
Zip:
01307
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+49 351 458 4425
Facility:
Name:
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0400)
Address:
City:
Berlin
Zip:
10117
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+4930450615092
Facility:
Name:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0504)
Address:
City:
Roma
Zip:
00168
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
390458128116
Facility:
Name:
Ospedale San Martino-U.O. Oncologia Medica 1 ( Site 0500)
Address:
City:
Genova
Zip:
16132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
390105553303
Facility:
Name:
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0502)
Address:
City:
Milan
Zip:
20133
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0390372405242
Facility:
Name:
Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli-UOSC Oncologia ( Site 0503)
Address:
City:
Naples
Zip:
80131
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
0817472223
Facility:
Name:
Ospedale San Raffaele-Oncologia Medica ( Site 0501)
Address:
City:
Milano
Zip:
20132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
390226435789
Facility:
Name:
Korea University Anam Hospital ( Site 2002)
Address:
City:
Seoul
Zip:
02841
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+8229206610
Facility:
Name:
Seoul National University Hospital-Urology ( Site 2000)
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+82220720361
Facility:
Name:
Samsung Medical Center-Urology ( Site 2001)
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
82234103557
Facility:
Name:
Auckland City Hospital ( Site 1901)
Address:
City:
Auckland
Zip:
1023
Country:
New Zealand
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
6493074949
Facility:
Name:
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1702)
Address:
City:
Lima
Zip:
15036
Country:
Peru
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+51956754968
Facility:
Name:
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0801)
Address:
City:
Bydgoszcz
Zip:
85-796
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48501446778
Facility:
Name:
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( S
Address:
City:
Warszawa
Zip:
02-781
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
48225462331
Facility:
Name:
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0806)
Address:
City:
Kielce
Zip:
SWK 25-734
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+48885997850
Facility:
Name:
Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 0805)
Address:
City:
Poznan
Zip:
WLK 61-731
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
607075929
Facility:
Name:
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0802)
Address:
City:
Koszalin
Zip:
75-581
Country:
Poland
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
943488930
Facility:
Name:
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 1006)
Address:
City:
Badalona
Zip:
08916
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
34934978925
Facility:
Name:
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1005)
Address:
City:
Madrid
Zip:
28034
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34913368263
Facility:
Name:
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1003)
Address:
City:
Pozuelo de Alarcon
Zip:
28223
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34914521987
Facility:
Name:
Hospital Universitari Vall d'Hebron-Oncology ( Site 1002)
Address:
City:
Barcelona
Zip:
08035
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34934894350
Facility:
Name:
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1001)
Address:
City:
Sevilla
Zip:
41013
Country:
Spain
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+34955012000
Facility:
Name:
Karolinska Universitetssjukhuset Solna ( Site 1101)
Address:
City:
Stockholm
Zip:
171 64
Country:
Sweden
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
46851770000
Facility:
Name:
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1102)
Address:
City:
Uppsala
Zip:
751 85
Country:
Sweden
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+46736869248
Facility:
Name:
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1200)
Address:
City:
Ankara
Zip:
06230
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+905334318506
Facility:
Name:
Memorial Ankara Hastanesi-Medical Oncology ( Site 1204)
Address:
City:
Ankara
Zip:
06520
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
905067521275
Facility:
Name:
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1201)
Address:
City:
Ankara
Zip:
06800
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
905555306271
Facility:
Name:
T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training (
Address:
City:
Istanbul
Zip:
34147
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
905069764412
Facility:
Name:
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1202)
Address:
City:
Istanbul
Zip:
34722
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
00905063509061
Facility:
Name:
Ege Universitesi Hastanesi-Medical Oncology ( Site 1203)
Address:
City:
Izmir
Zip:
35100
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+905337360674
Facility:
Name:
Torbay Hospital ( Site 1303)
Address:
City:
Torquay
Zip:
TQ2 7AA
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
4401803655376
Facility:
Name:
Royal Free Hospital ( Site 1300)
Address:
City:
London
Zip:
NW3 2QG
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
442077940500
Facility:
Name:
Gartnavel General Hospital-Clinical Trials Unit ( Site 1301)
Address:
City:
Glasgow
Zip:
G12 0YN
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
+447780777067
Facility:
Name:
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1302)
Address:
City:
London
Zip:
EC1A 7BE
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
020 7822 8498
Facility:
Name:
The Christie NHS Foundation Trust ( Site 1306)
Address:
City:
Manchester
Zip:
M20 4BX
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Study Coordinator
Phone:
441614468409
Start date:
March 28, 2024
Completion date:
April 8, 2031
Lead sponsor:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Collaborator:
Agency:
ModernaTX, Inc.
Agency class:
Industry
Source:
Merck Sharp & Dohme LLC
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06305767
https://www.merckclinicaltrials.com/
https://msd.trialsummaries.com/Study/StudyDetails?id=26155&tenant=MT_MSD_9011
